8-K: Tivic Health Completes Key Vagus Nerve Stimulation Study, Anticipates Breakthrough Findings

Tivic Health Systems, Inc. announced the completion of its Optimization Study for its non-invasive vagus nerve stimulation device, with breakthrough findings expected to be reported later this year and applied to an upcoming Phase I clinical trial.

Summary

• Tivic Health Systems, Inc. has completed all study visits for its Optimization Study of its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device.
• Initial findings from the study reinforce the importance of personalization for therapeutic efficacy.
• The company expects to release the full study results later this year.
• The study was conducted by The Feinstein Institute of Bioelectronic Medicine with the objective of identifying optimal device parameters, including frequency, amplitude, electrode positioning, and personalization.
• Key findings from earlier stages of this study were previously presented on March 4, 2025, at the Sixth Bioelectronic Medicine Summit.
• The insights gained from this study will be applied to Tivic's upcoming Phase I clinical trial.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment, emphasizing 'breakthrough findings,' 'more confident than ever' management statements, and significant market growth projections for the company's target segment. The completion of a key study and its application to future clinical trials are strong positive indicators, despite the inherent risks of early-stage R&D.

Positives

• Completion of all study visits for the Optimization Study, marking a significant R&D milestone.
• Initial findings indicate "breakthroughs" in understanding how to most effectively deliver vagus nerve stimulation.
• The study reinforces the importance of personalization for therapeutic efficacy, suggesting a refined and potentially more effective approach.
• Management expresses high confidence that their novel bioelectronic approach has the potential to form the basis of "compelling and highly differentiated treatments" for large patient populations with unmet clinical needs.
• The global VNS market is projected to grow significantly from $8.59 billion in 2021 to $21.3 billion in 2030, representing a 10.6% Compound Annual Growth Rate (CAGR).
• The peripheral nerve stimulation segment, which Tivic Health targets, is forecast to grow at an even faster 35% CAGR.
• Tivic Health has an existing FDA-approved product, ClearUP, for sinus pain and pressure, demonstrating prior regulatory success.
• The company's lead biopharma product candidate, Entolimod, has Fast Track and Orphan Drug designation from the FDA.

Risks

• Substantial risks and uncertainties inherent in forward-looking statements.
• Reliance on and guidance from the FDA and other regulatory authorities.
• Changes to the company's relationship with its partners.
• Failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations.
• Uncertainty regarding the future development of its ncVNS treatment, Entolimod, and Entolasta.
• Changes to the company's business strategy.
• Uncertainty regarding the timing and success of clinical trials and study results, including the ncVNS optimization study.
• Regulatory requirements and pathways for approval.
• Changes in the markets and industries in which the company does business.
• Consummation of any strategic transactions.
• The company's need for, and ability to secure when needed, additional working capital.
• The company's ability to maintain its Nasdaq listing.
• Changes in tariffs, inflation, legal, regulatory, political, and economic risks.

Future Outlook

Tivic Health expects to release the full results of its Optimization Study later this year. The breakthrough findings from this study, which provide key scientific understanding of effective vagus nerve stimulation delivery, will be applied to the company's upcoming Phase I clinical trial. Management is highly confident that their novel bioelectronic approach to VNS has the potential to form the basis of future compelling and highly differentiated treatments for large patient populations with unmet clinical needs.

Management Comments

• "This study has provided Tivic with key breakthroughs in the scientific understanding of how to most effectively deliver stimulation to the vagus nerve and thereby the modulation of the pathways implicated in many prevalent and debilitating diseases." Jennifer Ernst, CEO.
• "As we prepare to report these new findings, we are more confident than ever that our novel bioelectronic approach to VNS has the potential to form the basis of future compelling and highly differentiated treatments for large patient populations with unmet clinical needs." Jennifer Ernst, CEO.

Industry Context

Tivic Health operates within the rapidly growing bioelectronic medicine and immunotherapeutics sectors, specifically targeting the non-invasive vagus nerve stimulation (VNS) market. The global VNS market is projected to grow significantly, with the peripheral nerve stimulation segment, which Tivic Health targets, showing an even higher growth rate. This indicates a strong market opportunity for Tivic's innovative non-invasive devices, positioning them to address unmet clinical needs in chronic diseases where VNS is being studied beyond its current FDA-approved applications.

Comparison to Industry Standards

• The document highlights market growth estimates from Polaris Market Research and IDTechEx, projecting the global VNS market to reach $21.3 billion by 2030 (10.6% CAGR) and the peripheral nerve stimulation segment to grow at a 35% CAGR.
• However, the filing does not provide specific comparable company or project results to benchmark Tivic Health's current study findings or financial performance against industry peers. It focuses on the potential market size rather than competitive positioning based on specific outcomes.

Stakeholder Impact

• Shareholders: Positive news regarding R&D progress and potential for future treatments, which could enhance long-term value.
• Patients: Potential for novel, non-invasive treatments for prevalent and debilitating diseases, addressing unmet clinical needs.
• Employees: Continued work on promising R&D projects, potentially leading to future product development and growth opportunities.

Next Steps

• Release of full Optimization Study results later this year.
• Application of study findings to an upcoming Phase I clinical trial for the ncVNS device.

Key Dates

Recommendation

Keywords

Tivic Health Systems, TIVC, Vagus Nerve Stimulation, VNS, non-invasive, ncVNS, Bioelectronic Medicine, Clinical Study, Optimization Study, Feinstein Institute, Medical Device, Immunotherapeutics, Neurological Conditions, Chronic Disease, FDA, ClearUP, Entolimod, Peripheral Nerve Stimulation